Piyasa açık· · USD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
AppLovin (APP) holders have been through a rough stretch. The shares lost 54% over the past year, while the S&P 500 gained 16.8%. A $10,000 holding from a year ago is now worth about $4,560. In September, law firms began announcing a securities class action over what AppLovin told investors. For you, the bigger issue is a business problem, not the legal fight. So what is the biggest risk for AppLovin stock from here.
A nine-day slide has erased a significant chunk of the company's value.
One ad-tech stock has quietly broken away from two of its biggest peers in a year that has punished the sector, and the reasons behind that split reveal something important about where digital advertising is heading.
Investors grew more cautious about advertising demand, housing activity and emerging technology businesses.
One advertising technology stock climbed 46% this year while Trade Desk collapsed, and that split forces every shareholder to confront whether the buying side of programmatic advertising faces a temporary stumble or something far harder to recover from.
AppLovin buyers are wading back in after a brutal year-long selloff, but ad tech peers are barely flinching, and the reasons behind that split reveal a high-stakes debate about whether the bleeding has truly stopped.
The Trade Desk has underperformed other communication stocks, and analysts remain unsure about the stock’s outlook.
The number that should worry a holder of AppLovin (APP) stock is its revenue growth. Revenue rose 53% from a year earlier in the fiscal second quarter of 2026. That was the third quarter in a row of slower growth. The pace is still fast. But the stock is priced for growth to stay fast, which is why the slowdown matters.
Trade Desk has seen its share price fall sharply in recent years, and that slide naturally raises a question for anyone looking at the stock today. Is the current valuation still in line with the cash flows the business is expected to generate, or has the market moved ahead of what its underlying economics can support? Over the past 3 years, Trade Desk shares have declined 82.3%, which puts the focus squarely on whether the current price still reflects the cash the business can produce over...
Edgewater Research just raised a warning that AppLovin's growth engine may be hitting a wall, but Citi's latest data tells a very different story about where the company's next opportunity could come from.
The move gives life sciences advertisers a more streamlined way to bring specialized healthcare audiences into their broader digital media strategies.
Mechanical selling from an index rebalance is dragging Trade Desk lower, but the way its ad-tech peers are splitting tells a more specific story about which corner of programmatic advertising the market is actually repricing right now.
Expands programmatic access to 800,000 verified prescribers directly in the EHR workflow, making OptimizeRx’s point of care inventory directly available to advertisers using The Trade DeskWALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The T
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.
